Urinary monocyte chemoattractant protein-1 in renal disease

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2022-2030

  Kim, Min Jeong ^a   Tam, Frederick W K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Acute kidney injury; Chemokine; Diabetic nephropathy; Glomerulonephritis; Polycystic kidney disease; Urinary biomarker

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; STEROID;

ANTIBODY TITER; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DOWN REGULATION; GLYCEMIC CONTROL; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMORY T LYMPHOCYTE; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; PROTEIN URINE LEVEL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RENOVASCULAR HYPERTENSION; REVIEW; URETER OBSTRUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; CHEMOKINE CCL2; HUMANS; KIDNEY DISEASES;

ANIMALIA;

EID: 80053637659     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.07.023     Document Type: Review

References (88)

1. Duffield J.S. Macrophages and immunologic inflammation of the kidney. Semin Nephrol 2010, 30:234-254.
2. Van Coillie E., Van Damme J., Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 1999, 10:61-86.
3. Wu V.Y., Walz D.A., MaCoy L.E. Purification and characterization of human and bovine platelet factor 4. Prep Biochem 1977, 7:479-493.
4. Baggiolini M., Loetscher P. Chemokines in inflammation and immunity. Immunol Today 2000, 21:418-420.
5. Rollins B.J. Chemokines. Blood 1997, 90:909-928.
6. Wagner W., Roderburg C., Wein F., et al. Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. Stem Cells 2007, 25:2638-2647.
7. Hyduk S.J., Chan J.R., Duffy S.T., et al. Phospholipase C, calcium, and calmodulin are critical for α4β1 integrin affinity up-regulation and monocyte arrest triggered by chemoattractants. Blood 2007, 109:176-184.
8. Decramer S., Gonzalez de P.A., Breuil B., et al. Urine in clinical proteomics. Mol Cell Proteomics 2008, 7:1850-1862.
9. Gu L., Tseng S.C., Rollins B.J. Monocyte chemoattractant protein-1. Chem Immunol 1999, 72:7-29.
10. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001, 2:123-128.
11. Yadav A., Saini V., Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 2010, 411:1570-1579.
12. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein 1 (MCP-1): an overview. J Interferon Cytokine Res 2009, 29:313-326.
13. Melgarejo E., Medina M.Á., Sánchez-Jiménez F., Urdiales J.L. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol 2009, 41:998-1001.
14. Shin W.S., Szuba A., Rockson S.G. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002, 160:91-102.
15. Lubkowski J., Bujacz G., Boqué L., et al. The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat Struct Biol 1997, 4:64-69.
16. Paolini J.F., Willard D., Consler T., Luther M., Krangel M.S. The chemokines IL-8, monocyte chemoattractant protein-1, and I-309 are monomers at physiologically relevant concentrations. J Immunol 1994, 153:2704-2717.
17. Sung F.L., Zhu T.Y., Au-yeung K.K.W., Siow Y.L., Karmin O. Enhanced MCP-1 expression during ischemia/reperfusion injury is mediated by oxidative stress and NF-kappaB. Kidney Int 2002, 62:1160-1170.
18. Ruiz-Ortega M., Lorenzo O., Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int 2000, 57:2285-2298.
19. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008, 294:F697-F701.
20. Pentón-Rol G., Polentarutti N., Luini W., et al. Selective inhibition of expression of the chemokine receptor CCR2 in human monocytes by IFN-gamma. J Immunol 1998, 160:3869-3873.
21. Giunti S., Pinach S., Arnaldi L., et al. The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells. Kidney Int 2006, 69:856-863.
22. Giunti S., Tesch G.H., Pinach S., et al. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 2008, 51:198-207.
23. Viedt C., Dechend R., Fei J., et al. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1. J Am Soc Nephrol 2002, 13:1534-1547.
24. Burt D., Salvidio G., Tarabra E., et al. The monocyte chemoattractant protein-1/cognate CC chemokine receptor 2 system affects cell motility in cultured human podocytes. Am J Pathol 2007, 171:1789-1799.
25. Tarabra E., Giunti S., Barutta F., et al. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 2009, 58:2109-2118.
26. Jennette J.C. Crescentic glomerulonephritis. Heptinstall's Pathology of the Kidney 1998, 625-656. Lippincott-Raven, Philadelphia. 5th ed. J.C. Jennette, J.L. Olson, M.M. Schwartz, F.G. Silva (Eds.).
27. Alpers C.E., Hudkins K.L., Floege J., Johnson R.J. Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J Am Soc Nephrol 1994, 5:201-209.
28. Tam F.W.K., Karkar A.M., Smith J., et al. Differential expression of macrophage inflammatory protein-2 (MIP-2) and monocyte chemoattractant protein-1 (MCP-1) in experimental glomerulonephritis. Kidney Int 1996, 49:715-721.
29. Lloyd C.M., Minto A.W., Dorf M.E., et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997, 185:1371-1380.
30. Wada T., Yokoyama H., Furuichi K., et al. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J 1996, 10:1418-1425.
31. Lloyd C.M., Dorf M.E., Proudfoot A., Salant D.J., Gutierrez-Ramos J.C. Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis. J Leukoc Biol 1997, 62:676-680.
32. Tesch G.H., Schwarting A., Kinoshita K. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 1999, 103:73-80.
33. Zoja C., Corna D., Benedetti G., et al. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 1997, 8:720-729.
34. Hasegawa H., Kohno M., Sasaki M., et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003, 48:2555-2566.
35. Perez de Lema G., Maier H., Franz T.J., et al. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol 2005, 16:3592-3601.
36. Tesch G.H., Maifert S., Schwarting A., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas (lpr) mice. J Exp Med 1999, 190:1813-1824.
37. Shimizu S., Nakashima H., Masutani K., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology 2004, 43:1121-1128.
38. Kulkarni O., Pawar R., Purschke W., et al. Spiegelmer inhibition of CL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007, 18:2350-2358.
39. Chow F., Nikolic-Peterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
40. Chow F., Ozols E., Nikolic-Peterson D.J., Atkins R.C., Tesch G.H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004, 65:116-128.
41. Kanamori H., Matsubara T., Mima A., et al. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007, 360:772-777.
42. Nadeau K.C., Azuma H., Tilney N.L. Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1. Proc Natl Acad Sci U S A 1995, 92:8729-8733.
43. Cowley B.D., Ricardo S.D., Nagao S., Diamond J.R. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int 2001, 60:2087-2096.
44. Zhu X., Chade A.R., Krier J., et al. The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens 2009, 27:2063-2073.
45. Clauss S., Gross O., Kulkarni O., et al. Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen 4A3-deficient mice with autosomal recessive Alport nephropathy. J Pathol 2009, 218:40-47.
46. Kitagawa K., Wada T., Furuichi K. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004, 165:237-246.
47. Wada T., Furuichi K., Sakai N., et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004, 15:940-948.
48. Furuichi K., Wada T., Iwata Y., et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 2003, 14:2503-2515.
49. Furuichi K., Wada T., Iwata Y., et al. Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J Am Soc Nephrol 2003, 14:1066-1071.
50. Prodjosudjadi W., Gerritsma J.S., van Es L.A., Daha M.R., Bruijin J.A. Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis. Clin Nephrol 1995, 44:148-155.
51. Viedt C., Orth S.R. Monocyte chemoattractant protein-1 (MCP-1) in the kidney: does it more than simply attract monocytes?. Nephrol Dial Transplant 2002, 17:2043-2047.
52. Segerer S., Cui Y., Hudkins K., et al. Expression of the chemokine monocyte chemoattractant protein-1 and its receptor chemokine receptor 2 in human crescentic glomerulonephritis. J Am Soc Nephrol 2000, 11:2231-2242.
53. Cockwell P., Howie A.J., Adu D., Savage C.O.S. In situ analysis for C-C chemokine mRNA in human glomerulonephritis. Kidney Int 1998, 54:827-836.
54. Rovin B., Rumancik M., Tan L., Dickerson J. Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 1994, 71:536-542.
55. Wada T., Furuichi K., Segawa-Takaeda C., et al. MIP-1a and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999, 56:995-1003.
56. Tam F.W.K., Sanders J., George A., et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 2004, 19:2761-2768.
57. Ohlsson S., Bakoush O., Tencer J., Torffvit O., Segelmark M. Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. Mediators Inflamm 2009, 2009:584916.
58. Wada T., Yokoyama H., Su S., et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996, 49:761-767.
59. Noris M., Bernasconi S., Casiraghi F., et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995, 73:804-809.
60. Li Y., Tucci M., Narain S., et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006, 5:383-388.
61. Rovin B.H., Song H., Birmingham D.J., Hebert L.A., Yu C.Y., Nagaraja H.N. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005, 16:467-473.
62. Marks S.D., Shah V., Pilkington C., Tullus K. Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol 2010, 25:2283-2288.
63. Kiani A.N., Johnson K., Chen C., et al. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol 2009, 36:2224-2230.
64. Tucci M., Barnes E.V., Sobel E.S., et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004, 50:1842-1849.
65. Piotrowski P., Lianeri M., Gasik R., Roszak A., Olesinska M., Jagodzinski P.P. Monocyte chemoattractant protein-1-2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE. J Biomed Biotechnol 2010, 2010:130265.
66. Wada T., Furuichi K., Sakai N., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000, 58:1492-1499.
67. Wada T., Yokoyama H., Matsushima K., Kobayashi K. Chemokines in renal disease. Int Immunopharmacol 2001, 1:637-645.
68. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000, 58:684-690.
69. Morii T., Fujita H., Narita T., et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complications 2003, 17:11-15.
70. Wu C., Chen J., Lu K., et al. Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 2010, 411:700-704.
71. Ye S.D., Zheng M., Zhao L.L., et al. Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy. Eur J Clin Invest 2009, 39:980-985.
72. Tam F.W.K., Riser B., Meeran K., Rambow J., Pusey C.D., Frankel A.H. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 2009, 47:37-42.
73. Rovin B.H., Doe N., Tan L.C. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 1996, 27:640-646.
74. Stangou M., Alexopoulos E., Papagianni A., et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology 2009, 14:613-620.
75. Grandaliano G., Gesualdo L., Ranieri E., et al. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocyte recruitment. J Am Soc Nephrol 1996, 7:906-913.
76. Yokoyama H., Wada T., Furuichi K., et al. Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J Leukoc Biol 1998, 63:493-499.
77. Gesualdo L., Grandaliano G., Ranieri E., et al. Monocyte recruitment in cryoglonulinemic membranoproliferative glomerulonephritis: a pathogenetic role for monocyte chemotactic peptide-1. Kidney Int 1997, 51:155-163.
78. Yoshimoto K., Wada T., Furuichi K., Sakai N., Iwata Y., Yokoyama H. CD 68 and MCP-1/CCR2 expression of initial biopsies reflect the outcomes of membranous nephropathy. Nephron Clin Pract 2004, 98:c25-c34.
79. Grandaliano G., Gesualdo L., Ranieri E., Monno R., Stallone G., Schena F.P. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 1997, 63:414-420.
80. Prodjosudjadi W., Daha M.R., Gerritsma J.S.J., et al. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection. Nephrol Dial Transplant 1996, 11:1096-1103.
81. Dubinski B., Boratynska M., Kopec W., Szyber P., Patrzalek D., Klinger M. Activated cells in urine and monocyte chemotactic peptide-1 (MCP-1) - sensitive rejection markers in renal graft recipients. Transpl Immunol 2008, 18:203-207.
82. Zheng D., Wolfe M., Cowley B.D., Wallace D.P., Yamaguchi T., Grantham J.J. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2003, 14:2588-2595.
83. Meijer E., Boertien W.E., Nauta F.L., et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis 2010, 56:883-895.
84. Grandaliano G., Gesualdo L., Bartoli F., et al. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int 2000, 58:182-192.
85. Munshi R., Johnson A., Siew E.D., et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 2011, 22:165-175.
86. Norden A.G.W., Lapsley M., Lee P.J., et al. Glomerular protein sieving and implication for renal failure in Fanconi syndrome. Kidney Int 2001, 60:1885-1892.
87. Copelovitch L., Nash M.A., Kaplan B.S. Hypothesis: Dent disease is an underrecognized cause of focal glomerulosclerosis. Clin J Am Soc Nephrol 2007, 2:914-918.
88. Yanagida H., Ikeoka M., Kuwajima H., et al. A boy with Japanese Dent's disease exhibiting abnormal calcium metabolism and osseous disorder of the spine: defective megalin expression at the brushborder of renal proximal tubules. Clin Nephrol 2004, 62:306-312.